Repligen Reports Third Quarter Fiscal Year 2009 Financi...(al calls. Participants must provide the...)

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

                               REPLIGEN CORPORATION
                             STATEMENTS OF OPERATIONS
                                    (Unaudited)

                             Three months ended         Nine months ended
                                December 31,               December 31,
                             -------------------        ------------------
                             2008          2007         2008         2007
                             ----          ----         ----         ----
    Revenue:
      Product revenue      $3,293,615    $4,562,975  $11,971,261  $15,450,799
      Royalty and other
       revenue              2,723,983       101,390   12,796,505      544,705
                            ---------       -------   ----------      -------
        Total revenue       6,017,598     4,664,365   24,767,766   15,995,504

    Operating expenses:
      Cost of product
       revenue              1,286,658     1,730,464    4,343,703    4,857,191
      Cost of royalty
       and other revenue      285,941             -      821,552            -
      Research and
       development          3,579,229     1,591,796    8,126,774    4,883,116
      Selling, general
       and
       administrative      
'/>"/>
SOURCE  Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 
Related biology technology :

1. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
3. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
4. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
5. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
6. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
7. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
10. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results